Ariad Pharmaceuticals Inc fka ARIA

[Bxofscidad]

Peter:


Aside from 3rd line, don't you think that if the final Phase 11 results are fairly consistant with the final results of Phase 1, that almost every patient who is still alive with the T315i mutation will be put on Ponatinib as soon as it is approved by the FDA? I would assume that when Ponatinib is approved, the initial sales figures will be larger than most people and analysts are expecting, especially if they are only looking at Ponatinib as merely a 3rd line drug.


JMHO
Barry